What Solinea does

Solinea sp. z o.o. is a privately-held Polish pharmaceutical company headquartered in Ciecierzyn (Elizówka), Poland, operating as a marketing authorization holder (MAH) and product developer with approximately 250 employees and 20 years of operating history. The company markets a portfolio of 150+ products across five regulated categories: prescription medicines, over-the-counter (OTC) medications, dietary supplements, medical devices, and cosmetics, with therapeutic focus on respiratory health (inhalation solutions, nasal sprays), ENT (ear/eye drops), pediatric and maternal health, and fertility support (the Fertistim line featuring patented Caronositol Fertility®). Core product lines include the Nebu-dose inhalation range (Isotonic, Hipertonic, Plus, Baby, Hialuronic), Muconasin nasal spray, Mufluil Hipertonic (N-acetylcysteine formulation), Ectodose / Ecto Respira (hypertonic saline with ectoine), Otoargent / Solwax Active (ear care), and the Fertistim fertility supplement family.

Solinea operates a capital-light asset model in which physical manufacturing is outsourced to four specialized European partners — Pharma Line S.r.l. (Italy), Unolab Manufacturing S.l. (Spain), bitop AG (Germany), and Arkona Trade and Science (Poland) — while Solinea retains the marketing authorization, brand, and commercialization rights in Poland. The go-to-market is a hybrid enterprise field-sales model (Pharmaceutical and Medical Representatives covering 20+ Polish cities calling on pharmacies and healthcare professionals) combined with a pharmacy distribution channel (1,500+ business partners including chains and independents) and a direct-to-consumer e-commerce channel at nebudose.pl. Consumer demand is driven in part by a content-marketing ecosystem of six owned health-education portals covering pediatric, sinus, midwifery, wound care, and general health topics.

Revenue is generated through unit-priced sales of OTC, supplement, and medical device products at retail (e.g., Muconasin nasal spray at approximately PLN 27–35 per unit), prescription-medicine sales through pharmacies (with reimbursement set by the Polish National Health Fund, NFZ), and cosmetics. No external funding rounds, M&A activity, or institutional investors are disclosed; the company is independently owned with registered share capital of PLN 200,000. Customer concentration is low, with the end-purchaser being individual consumers across a fragmented pharmacy and DTC channel, though upstream supply is concentrated among a small set of foreign manufacturers.

Name

Solinea

Legal name

Solinea sp. z o.o.

Website

https://solinea.pl

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Solinea is a privately-held Polish pharmaceutical marketing authorization holder distributing 150+ products — including respiratory, ENT, pediatric, and fertility lines — through 1,500+ pharmacy partners and a field sales force, with manufacturing outsourced to specialized European producers.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

OTC & Consumer Health Distributors (HLAIAJAC)

akta.pro secondary industries

Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Pharmaceutical distribution
• Generic pharmaceuticals
• Inhalation solutions
• Dietary supplements
• Medical devices

Headquarters

HQ city

Ciecierzyn

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Prescription medicines (Rx): Revenue from prescription-only pharmaceutical products sold through pharmacies, primarily in Poland.
2. OTC and medical device products: Revenue from over-the-counter medicines and medical devices (inhalation solutions, nasal sprays, ear drops, eye drops) sold through pharmacy distribution and direct-to-consumer e-commerce.
3. Dietary supplements: Revenue from dietary supplement products (e.g., Fertistim mio, Fertistim ovu, Lactimal) sold through pharmacy and retail channels.
4. Cosmetics: Revenue from cosmetic products sold through pharmacy and retail channels.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Solinea is a Polish pharmaceutical company that holds marketing authorizations for a portfolio of 150+ healthcare products spanning prescription medicines, OTC drugs, medical devices (notably inhalation solutions such as the Nebu-dose line), dietary supplements (including the Fertistim fertility range), and cosmetics. The company brands and distributes products manufactured by partner producers in Italy, Spain, Germany, and Poland, selling them primarily through Polish pharmacies and its own e-commerce portal (nebudose.pl) while targeting healthcare professionals via a national field sales force.

Product overview

Solinea is a pharmaceutical company operating in the healthcare sector with a portfolio of over 150 products. The portfolio is organized across five main product categories: prescription drugs (leki na receptę), over-the-counter medications (leki OTC), dietary supplements (suplementy diety), medical devices (wyroby medyczne), and cosmetics (kosmetyki). Products address various therapeutic areas including digestive system (układ pokarmowy), respiratory/inhalation therapies, ear care, eye care, urinary tract health, joints and bones, vitamins and minerals, and fertility support. The medical device portfolio includes the Nebu-dose product line (Nebu-dose Hialuronic, Nebu-dose Hipertonic, Nebu-dose Plus, Nebu-dose Baby, Nebu-dose Isotonic, Nebu Pulmo), inhalation products (Mufluil Hipertonic, Ecto Respira, Ectodose), ENT products (Otoargent, Solwax Active, Muconasin), and others (Karpal CBD, Softamil, Reflu-G baby). The dietary supplements include fertility products (Fertistim mio, Fertistim ovu, Lactimal) and others. OTC medications include Erdosol Respiro for cough and cold symptoms. Products are categorized by health issues including allergy, pain, urinary-genital tract, throat, bacterial infections, inhalation, oral cavity, cough, rhinitis, eyes, immunity, cold, skin wounds, hearing, joints and bones, nervous system, digestive system, and vitamins/minerals.

Differentiator

Problem solved

Functional benefit

Products and services

• Reflu-G baby Cookie-flavoured oral solution medical device (210 ml) for pediatric digestive system support.
• Iodim Eye-drop medical device (10 ml) for eye care.
• Softamil Oral solution medical device (250 ml) for digestive system support.
• Karpal CBD Emulsion medical device (30 ml) for joints and bones support.
• Fertistim mio Neutral-flavoured powder dietary supplement (30 sachets) supporting urinary tract health and vitamins/minerals, featuring the patented Caronositol Fertility formulation.
• Lactimal Vanilla-flavoured powder dietary supplement (30 sachets) providing vitamins and minerals for lactation support.
• Fertistim ovu Forest fruit-flavoured powder dietary supplement (30 sachets) supporting urinary tract health and fertility, using the patented Caronositol Fertility formulation.
• Mufluil Hipertonic Sterile medical-device solution for nasal instillation and nebulization containing N-acetylcysteine and hypertonic sodium chloride (3% NaCl) that dilutes thick and viscous mucus through mucolytic and osmotic action.
• Nebu-dose Hialuronic Hypertonic saline inhalation solution with hyaluronic acid, indicated to facilitate movement of respiratory secretions and improve breathing comfort in bronchiolitis, acute bronchitis, cystic fibrosis, and COPD.
• Ecto Respira Inhalation medical device combining hypertonic saline with ectoine for alleviation of symptoms in bronchiolitis, acute bronchitis, cystic fibrosis, asthma, COPD, and allergic respiratory reactions.
• Ectodose Hypertonic saline with ectoine inhalation medical device for supportive treatment of inflammatory and respiratory conditions including allergic and non-allergic asthma, bronchitis, and COPD.
• Nebu Pulmo Inhalation medical device for patients with bronchiolitis, acute bronchitis, cystic fibrosis, asthma, COPD, and allergic airway conditions, facilitating movement of respiratory secretions.
• Nebu-dose Hipertonic Hypertonic saline solution (3% NaCl) inhalation medical device to facilitate movement of secretions in bronchiolitis, acute bronchitis, cystic fibrosis, and COPD.
• Nebu-dose Plus Inhalation medical device to facilitate movement of respiratory secretions and improve breathing comfort in bronchiolitis, acute bronchitis, cystic fibrosis, and COPD.
• Nebu-dose Baby Age-appropriate inhalation medical device for infants, facilitating movement of respiratory secretions in bronchiolitis, acute bronchitis, cystic fibrosis, and COPD.
• Nebu-dose Isotonic Isotonic saline solution (0.9% NaCl) inhalation medical device for facilitating movement of respiratory secretions and improving breathing comfort in bronchiolitis, acute bronchitis, cystic fibrosis, and COPD.
• Erdosol Respiro OTC medication containing erdosteine, a mucolytic that reduces viscosity of bronchial secretions and facilitates expectoration, indicated for acute and chronic inflammatory respiratory-tract diseases.
• Otoargent Ear-drop medical device supporting treatment of inflammatory conditions of the external auditory canal caused by bacterial and fungal infections.
• Solwax Active Ear-care medical device in spray and drop forms for ear wax removal and reducing the risk of ear inflammation.
• Muconasin Nasal spray medical device with N-acetylcysteine and hypertonic saline (3% NaCl) that liquefies and removes congested nasal and sinus secretions, indicated for rhinitis, acute and chronic sinusitis, and other congested respiratory conditions.

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• Pharma Line S.r.l.coreTechnology or IntegrationItalian pharmaceutical manufacturer producing Muconasin nasal spray and Mufluil Hipertonic inhalation solution. Solinea is the marketing authorization holder and advertiser (Podmiot Prowadzący Reklamę) for these products in Poland, while Pharma Line S.r.l. is the manufacturer.
• Unolab Manufacturing S.l.coreTechnology or IntegrationSpanish pharmaceutical manufacturer producing the Nebu-dose inhalation solution line (Nebu-dose Isotonic, Nebu-dose Hipertonic, Nebu-dose Plus, Nebu-dose Baby, Nebu-dose Hialuronic), Ecto Respira, and Nebu Pulmo. Solinea serves as the marketing authorization holder and advertiser in Poland.
• bitop AGcoreTechnology or IntegrationGerman biotechnology company manufacturing Ectodose — a hypertonic saline solution with ectoine for inhalation. Solinea is the marketing authorization holder and advertiser in Poland.
• Arkona Trade and Science Sp.j.coreTechnology or IntegrationPolish pharmaceutical company manufacturing Otoargent (ear drops) and Solwax Active (ear wax removal products — spray and drops). Solinea is the marketing authorization holder and advertiser in Poland.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Zentiva: CEE-focused generics and OTC pharmaceutical company with strong Polish operations distributing through Polish pharmacies. Comparable to Solinea in channel and therapeutic-area breadth, with broader geographic reach across Central and Eastern Europe.
• Walmark: CEE-focused dietary supplement and OTC company headquartered in the Czech Republic with Polish distribution. Comparable to Solinea in supplement-led portfolio, pharmacy-channel go-to-market, and category overlap in fertility and women's health.

Broad incumbents

• Polpharma: Largest Polish pharmaceutical manufacturer with a broad Rx, OTC, and consumer health portfolio distributed via Polish pharmacies. A broader incumbent than Solinea but operates in the same channels with overlapping OTC and supplement categories.
• STADA Poland: Polish operations of European generics and consumer healthcare group STADA, distributing OTC and generic Rx products through Polish pharmacies. Comparable in channel model and OTC/consumer-health mix, with broader European footprint.
• Reckitt Benckiser Poland: Multinational consumer health company distributing OTC and health products (respiratory, digestive, vitamins) through Polish pharmacies and retail. Comparable to Solinea in pharmacy-channel consumer health distribution and OTC/supplement categories, though part of a much larger global portfolio.
• Teva Pharmaceuticals Polska: Polish arm of global generics leader Teva, distributing prescription and OTC pharmaceuticals through Polish pharmacies and wholesalers. Comparable to Solinea in pharmaceutical distribution scale and pharmacy-channel focus, though broader in Rx.

Direct peers

• Omega Pharma Poland (Perrigo): Specialist OTC and personal-care company with Polish operations distributing consumer health products through pharmacies. Directly comparable to Solinea in OTC-led product strategy and pharmacy-channel distribution in Poland.
• USP Zdrowie: Polish pharmaceutical manufacturer and distributor of OTC, supplements, and medical devices. Closely comparable to Solinea in product mix (OTC + supplements + medical devices), Polish pharmacy-channel distribution model, and focus on pediatric and family health categories.
• Hasco-Lek: Polish pharmaceutical company producing and distributing OTC drugs, dietary supplements, and medical devices primarily through Polish pharmacies. Comparable to Solinea in operating model, channel focus, and product category breadth across consumer health.
• Aflofarm Farmacja Polska: One of the largest Polish OTC pharmaceutical and dietary supplement companies, distributing through Polish pharmacies with a broad consumer-health portfolio. Directly comparable to Solinea in target channels, customer segments, and broad OTC/supplement portfolio strategy.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/solineapl
• Facebookfacebook.com/Solineapl
• LinkedInlinkedin.com/company/solineapl

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solinea